BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

798 related articles for article (PubMed ID: 29757368)

  • 1. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
    Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
    Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The β
    Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
    Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
    Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development.
    Ci X; Hao J; Dong X; Xue H; Wu R; Choi SYC; Haegert AM; Collins CC; Liu X; Lin D; Wang Y
    Cells; 2020 Jun; 9(6):. PubMed ID: 32512818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
    Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
    J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
    Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
    Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer.
    Crea F; Venalainen E; Ci X; Cheng H; Pikor L; Parolia A; Xue H; Nur Saidy NR; Lin D; Lam W; Collins C; Wang Y
    Epigenomics; 2016 May; 8(5):721-31. PubMed ID: 27096814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ONECUT2 is a driver of neuroendocrine prostate cancer.
    Guo H; Ci X; Ahmed M; Hua JT; Soares F; Lin D; Puca L; Vosoughi A; Xue H; Li E; Su P; Chen S; Nguyen T; Liang Y; Zhang Y; Xu X; Xu J; Sheahan AV; Ba-Alawi W; Zhang S; Mahamud O; Vellanki RN; Gleave M; Bristow RG; Haibe-Kains B; Poirier JT; Rudin CM; Tsao MS; Wouters BG; Fazli L; Feng FY; Ellis L; van der Kwast T; Berlin A; Koritzinsky M; Boutros PC; Zoubeidi A; Beltran H; Wang Y; He HH
    Nat Commun; 2019 Jan; 10(1):278. PubMed ID: 30655535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
    BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms.
    Mather RL; Parolia A; Carson SE; Venalainen E; Roig-Carles D; Jaber M; Chu SC; Alborelli I; Wu R; Lin D; Nabavi N; Jachetti E; Colombo MP; Xue H; Pucci P; Ci X; Hawkes C; Li Y; Pandha H; Ulitsky I; Marconett C; Quagliata L; Jiang W; Romero I; Wang Y; Crea F
    Mol Oncol; 2021 Jul; 15(7):1921-1941. PubMed ID: 33793068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.
    Li Y; Donmez N; Sahinalp C; Xie N; Wang Y; Xue H; Mo F; Beltran H; Gleave M; Wang Y; Collins C; Dong X
    Eur Urol; 2017 Jan; 71(1):68-78. PubMed ID: 27180064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
    Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
    World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

  • 14. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
    Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
    Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
    [No Abstract]   [Full Text] [Related]  

  • 15. LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling.
    Luo J; Wang K; Yeh S; Sun Y; Liang L; Xiao Y; Xu W; Niu Y; Cheng L; Maity SN; Jiang R; Chang C
    Nat Commun; 2019 Jun; 10(1):2571. PubMed ID: 31189930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma.
    Ostano P; Mello-Grand M; Sesia D; Gregnanin I; Peraldo-Neia C; Guana F; Jachetti E; Farsetti A; Chiorino G
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32041153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression.
    Lee AR; Li Y; Xie N; Gleave ME; Cox ME; Collins CC; Dong X
    Oncotarget; 2017 Apr; 8(17):27966-27975. PubMed ID: 28427194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma.
    Liang L; Xia W; Yao L; Wu Q; Hua L; Cheng G; Wang Z; Zhao R
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108267. PubMed ID: 34740081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of differential expression profiles of mRNAs and lncRNAs and identification of a 14-lncRNA prognostic signature for patients with colon adenocarcinoma.
    Xing Y; Zhao Z; Zhu Y; Zhao L; Zhu A; Piao D
    Oncol Rep; 2018 May; 39(5):2365-2375. PubMed ID: 29565464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA Splicing of the BHC80 Gene Contributes to Neuroendocrine Prostate Cancer Progression.
    Li Y; Xie N; Chen R; Lee AR; Lovnicki J; Morrison EA; Fazli L; Zhang Q; Musselman CA; Wang Y; Huang J; Gleave ME; Collins C; Dong X
    Eur Urol; 2019 Aug; 76(2):157-166. PubMed ID: 30910347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.